53 Results for "

CYP2C8

" in MedChemExpress (MCE) Product Catalog:
Products (53)

53 Results for "CYP2C8" in MCE Product Catalog:

  • Isoforms Recommended:
36
36 Publications Verification
Cat. No.: HY-17356
CAS No.: 49562-28-9
Research Areas:  

Cardiovascular Disease Cancer

Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0319
CAS No.: 115841-09-3
Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (CYP2J2), with Kis of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N6065
CAS No.: 73069-27-9
Synonyms: (+)-Praeruptorin A
Praeruptorin A ((+)-Praeruptorin A) is an orally active isomer of (±)-Praeruptorin A (HY-N0081). Praeruptorin A also acts as a Calcium channel blocker. Praeruptorin A can be isolated from Peucedanum. Praeruptorin A serves as a substrate for CYP3A4. Praeruptorin A downregulates NMDA receptors containing GluN2B and inhibits neuronal Apoptosis. Praeruptorin A mediates vasodilation, inhibits vascular hypertrophy and reduces blood pressure. Praeruptorin A can be used in research related to neurological diseases, myocardial ischemia, heart failure, exertional angina, renovascular hypertension and spontaneous hypertension .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-129993
CAS No.: 91683-38-4
Purity:  98.79%
Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive P450 (CYP) isoform CYP2C8 inhibitor with an IC50 of 4.07 μM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135334
CAS No.: 2230757-47-6
Purity:  98.41%
Research Areas:  

Cancer

ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135331
CAS No.: 1332391-11-3
Purity:  99.68%
N-Desmethyl-Apalutamide, the major active metabolite of Apalutamide (HY-16060), is a selective competitive inhibitor of androgen receptor. N-Desmethyl-Apalutamide is catalyzed by CYP3A4 and CYP2C8 enzymes. The plasma protein binding rate of N-Desmethyl-Apalutamide reaches 95%, with albumin as the primary binding protein. N-Desmethyl-Apalutamide is suitable for prostate cancer-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148352
CAS No.: 423150-91-8
Purity:  98.83%
Target:  

PPAR

Research Areas:  

Cancer

BAY-4931 is a potent, covalent and selective PPARγ inverse-agonist with an IC50 of 0.17 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-114759
CAS No.: 206052-02-0
Purity:  99.27%
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC50s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-125348
CAS No.: 153212-75-0
Purity:  99.93%
Target:  

Drug Metabolite

Research Areas:  

Cancer

6α-Hydroxy paclitaxel is one of the main metabolites of Paclitaxel (PTX) (HY-B0015), and it is generated by the liver cytochrome P450 enzyme CYP2C8. 6α-Hydroxy paclitaxel has bone marrow toxicity, but it can enhance the cytotoxicity of PTX against leukemia cells without causing cell toxicity. 6α-Hydroxy paclitaxel can be used in leukemia research .
loading...
    loading...
Cat. No.: HY-N5132
CAS No.: 7787-20-4
(-)-Fenchone is a bicyclic monoterpene and serves as a substrate for human liver microsomal cytochrome P450 enzymes CYP2A6 and CYP2B6. (-)-Fenchone is not metabolized by human CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 enzymes. (-)-Fenchone undergoes hydroxylation to produce 6-exo-hydroxyfenchone, 6-endo-hydroxyfenchone, and 10-hydroxyfenchone. During the metabolism of (-)-Fenchone, CYP2A6 may play a more important role than CYP2B6 .
loading...
    loading...
Cat. No.: HY-135335
CAS No.: 874908-14-2
Purity:  98.09%
Target:  

Drug Metabolite

Research Areas:  

Metabolic Disease

3'-Hydroxy Repaglinide is the major CYP2C8 metabolite of Repaglinide (HY-15209). Repaglinide is a carbamoylmethylbenzoic acid (CMBA) derivative that acts on type 2 diabetes .
loading...
    loading...
Cat. No.: HY-100641
CAS No.: 5719-85-7
Purity:  99.69%
Synonyms: Hydroxytolbutamide
Research Areas:  

Metabolic Disease Cancer

4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic .
loading...
    loading...
Cat. No.: HY-147294
CAS No.: 1435480-40-2
Purity:  99.74%
Synonyms: ACT-539313
Nivasorexant (ACT-539313) is an orally active, blood-brain barrier penetrant, selective orexin OX1R inhibitor. Nivasorexant specifically blocks central OX1Rs without affecting OX2Rs, and exhibits competitive inhibitory activity against CYP2C8, CYP2C9, CYP2C19 and CYP3A4 (IC50 values are 25 μM, 8.6 μM, 1.6 μM, 19 μM/44 μM, respectively). Nivasorexant significantly reduces binge-like eating behavior of highly palatable food in rat models and has long-acting properties. Nivasorexant shows no relevant off-target activity against over 130 selected proteins, exhibits favorable safety profiles, and can be used for studies related to binge eating disorder .
loading...
    loading...
Cat. No.: HY-W013268
CAS No.: 790676-40-3
Synonyms: (+)-N-3-Benzylnirvanol
Target:  

Cytochrome P450

Research Areas:  

Metabolic Disease

(S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a Ki of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 .
loading...
    loading...
Cat. No.: HY-116862
CAS No.: 97744-44-0
Purity:  99.54%
Synonyms: DBF
Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its Km value of 0.87-1.9 μM (Ex=485 nm,Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .
loading...
    loading...
Cat. No.: HY-124542
CAS No.: 69002-84-2
Research Areas:  

Cancer

5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .
loading...
    loading...
Cat. No.: HY-17356S
CAS No.: 1092484-56-4
Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
loading...
    loading...
Cat. No.: HY-125348S
CAS No.: 1315376-90-9
Purity:  99.31%
6α-Hydroxy Paclitaxel-d5 is the deuterium labeled 6α-Hydroxy paclitaxel. 6α-Hydroxy paclitaxel is one of the main metabolites of Paclitaxel (PTX) (HY-B0015), and it is generated by the liver cytochrome P450 enzyme CYP2C8. 6α-Hydroxy paclitaxel has bone marrow toxicity, but it can enhance the cytotoxicity of PTX against leukemia cells without causing cell toxicity. 6α-Hydroxy paclitaxel can be used in leukemia research.
loading...
    loading...
Cat. No.: HY-147422
CAS No.: 2365178-28-3
Purity:  99.59%
Synonyms: XNW3009
Target:  

URAT1

Xininurad is a potent orally active URAT1 inhibitor with an IC50 of 7.17 nM. Xininurad inhibits URAT1 activity to reduce serum uric acid levels and increase urinary uric acid excretion. Xininurad can be used for the research of hyperuricemia and gout .
loading...
    loading...
Cat. No.: HY-163438
CAS No.: 1951431-34-7
BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research .
loading...
    loading...